lefcar l carnitine L-Carnitine — Global Medics USA® Liquid L-Carnitine 1000 Mg, NOW

International J Dev Neurosci 2006

The distinction is critical

However, there were some limitations in the previous studies regarding levocarnitine treatment in the dialysis population, including sample size, adequacy of study design, and definition of target diseases

this heterogeneity could explain why results from trials addressing classic neuropathic pain states do not translate to CIPNP Clinical trial designers in academia and industry are encouraged to implement sensory profiling in patient stratification to tailor the analgesic treatment according to the individual underlying mechanisms of CIPNP Mechanisms involved in CIPNP include disruption of axonal transport, altered ion channel and receptor activity, neuronal injury and inflammation, oxidative stress, and mitochondrial damage Suggestions for mechanism-based therapy of CIPNP include duloxetine for oxaliplatin-induced CIPNP, and combination of neuroprotective and anti-inflammatory substances for CIPNP caused by paclitaxel or vincristine Abstract Chemotherapy-induced peripheral neuropathic pain (CIPNP)a severe adverse effect observed in up to 80% of patients during treatment with antineoplastic drugslimits the tolerable dose of cytostatics, and can lead to discontinuation of chemotherapy